Endocrine Abstracts

Neuroendocrine tumors are rare in young patients and usually have favorable course. We present a case of young, 13-year-old girl diagnosed with insulinoma. The diagnosis was stated on the basis of the presence of neuroglycopenic symptoms. An abdominal CT scan demonstrated a tumor localized in the head of pancreas. The patient received diazoxide as a preparation to surgery. Therapy was effective, but discontinued due to side effects. Patient underwent the Whipple operation. Dur...

Mutations in the RET protooncogene cause familial cases of medullary thyroid cancer, which in some cases coexists with pheochromocytoma and primary hyperparathyreoidism as the MEN2A syndrome.Aim of the study: Evaluation of frequency of pheochromocytomas and their clinical course in the RET protooncogene mutations carriers.Material: One hundred and seventy nine patients, among them 109 probands and 70 family members in...

Introduction: The molecular events involved in the formation of parathyroid adenomas are not well understood. Two genes, cyclin D1 (CCND1) and MEN-1, have been established as having major roles in parathyroid tumorigenesis. Tumor suppressor gene HRPT2 is frequently mutated in parathyroid carcinoma. The aim of our study was to analyze HRPT2 expression in parathyroid adenomas and in residual normal/atrophic parathyroid tissue and to relate it to other...

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...

Introduction: BRAFV600E mutation is the most frequent alteration in papillary thyroid carcinoma (PTC). Although its relation to factors of poor prognosis was demonstrated in many studies the use of BRAF as a predictive marker in clinical treatment of PTC patients is controversial. The aim of our study was to analyze molecular consequences of BRAFV600E mutation in a transgenic mouse model performed for this purpose and to refer the obtained results to...

Introduction: Follicular adenomas (FTA) and carcinomas (FTC) are thyroid tumours that are indistinguishable in the fine needle aspiration biopsy (FNAB). In our previous research we concentrated on post-operative material and developed the classifier, which discriminates the FTC and FTA, based on formalin-fixed paraffin-embedded (FFPE) material. The classifier was based on expression of five genes and gave the promising sensitivity of 71% and specificity of 72%. The aim of the ...

Introduction: Discovery of V600E (BRAFT1799A) mutation in papillary thyroid carcinoma (PTC) widened our knowledge about mechanisms of its molecular initiation. It has been revealed that activating mutations of the BRAF kinase are much more frequent in PTC than RET rearrangements.Aim of the study: Estimation of V600E BRAF mutation frequency in PTC and analysis of differences in gene expression profile between papillary thyroid car...

Background: Parathyroid carcinoma (PC) is a rare endocrine malignancy affecting 0.5–5% of all patients with primary hyperparathyroidism. Due to the rarity of PC there is still lack of prognostic implications of the disease and clear consensus regarding management. Our purpose was to evaluate prognostic factors and treatment outcomes of patients treated at the Department of Nuclear Medicine and Endocrine Oncology.Methods: The target group covered 44 ...

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

Background: Although recombinant human TSH (rhTSH) is widely used to aid radioiodine treatment of differentiated thyroid cancer (DTC), however, there are data on its effectivness in children and adolescents with DTC.The aim of our retrospective study was to evaluate effectiveness and safety of rhTSH aided radioiodine treatment in DTC patients 18 years of age or younger.Material and Methods: Fifty five children/adolescents (median a...